Marshall Edwards' phenoxodiol fails Phase III ovarian cancer trial
This article was originally published in Scrip
Executive Summary
Marshall Edwards' lead drug candidate the chemosensitiser phenoxodiol failed to differentiate from placebo in a Phase III trial in women with recurrent ovarian cancer. Enrolment into the OVATURE trial had been halted prematurely last year, due to slower than anticipated patient recruitment rates, consequently weakening its statistical power. Nevertheless, the news sent the company's share price falling by 50%, to $2.00 on the Nasdaq on 1 June.